Search

Your search keyword '"Machet L"' showing total 899 results
Start Over Author "Machet L"
899 results on '"Machet L"'

105. High-frequency ultrasound quantification of acute radiation dermatitis: pilot study of patients undergoing radiotherapy for breast cancer

Author

Reymond, Maud, Barbier, Louise, Salame, Ephrem, Besh, Camille, Dumortier, Jérome, Pageaux, Georges-Philippe, Bureau, Christophe, Dharancy, Sébastien, Vanlemmens, Claire, Abergel, Armand, Woehl Jaegle, Marie-Lorraine, Magro, Pascal, Patat, Frederic, Laurent, Emeline, Perarnau, Jean-Marc, Garnier, M., Champeaux, E., Boehm, A., Briard, O., Wachter, T., Vaillant, L., Bens, G., Machet, L., Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Departement d'Hépato-Gastroentérologie et Cancérologie Digestive [CHRU Tours], CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), service d'Hépato-gastro-entérologie, Hospices Civiles de Lyon-Hôpital Edouard Heriault, Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépatologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Pascal (IP), SIGMA Clermont (SIGMA Clermont)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre National de la Recherche Scientifique (CNRS), SIGMA Clermont, Hépatologie Gastro-Entérologie, Université de Tours (UT), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Éducation Éthique Santé EA 7505 (EES), Association pour la Pêche et la Protection des Milieux Aquatiques (AAPPMA), and Hôpital Bichat

Subjects
medicine.medical_specialty, medicine.medical_treatment, Breast Neoplasms, Pilot Projects, Dermatology, [SHS]Humanities and Social Sciences, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Edema, Humans, Medicine, ComputingMilieux_MISCELLANEOUS, Aged, Ultrasonography, Univariate analysis, integumentary system, business.industry, Ultrasound, Lumpectomy, Middle Aged, medicine.disease, Phototype, Radiation therapy, ROC Curve, 030220 oncology & carcinogenesis, Acute Disease, Female, Radiology, Radiodermatitis, medicine.symptom, business, Complication
Abstract

Background Acute radiation dermatitis (ARD) is a frequent complication after breast cancer radiotherapy and is usually assessed by semi-quantitative clinical scores, which may be subject to inter-observer variability. High-frequency ultrasound imaging of the skin can reliably quantify thickness and edema in diseased skin. We aimed to compare the relative increase in dermal thickness of the irradiated zone in breast-cancer patients undergoing radiotherapy, with clinical severity. Methods A consecutive series of patients undergoing treatment for breast cancer by lumpectomy and radiotherapy in a 6-month period also underwent clinical and ultrasound evaluation of ARD. Results We included 34 female patients 17 had grade 1 (group 1), 17 had grade 2 or grade 3 ARD (group 2). The mean relative increase in dermal thickness in irradiated skin (RIDTIS) was greater for group 2 than 1: 0.53 vs 0.29 mm (P=.023). On univariate analysis, ARD was associated with skin phototype, breast volume and RIDTIS, and on multivariable analysis, breast volume and age remained predictive of the disease. Conclusion Patients with more severe dermatitis showed significantly increased dermal thickness. Dermal thickness is a quantitative variable that could help quantify the efficacy of drugs and improve the treatment of this disease in patients undergoing radiotherapy.

Published
2017
Full Text
View/download PDF

107. An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

Author

Saiag, P., primary, Robert, C., additional, Grob, J.J., additional, Mortier, L., additional, Dereure, O., additional, Lebbe, C., additional, Mansard, S., additional, Grange, F., additional, Neidhardt, E.-M., additional, Lesimple, T., additional, Machet, L., additional, Bedane, C., additional, Jeudy, G., additional, Aubin, F., additional, Dreno, B., additional, Szenik, A., additional, Denden, A., additional, and Dutriaux, C., additional

Published
2018
Full Text
View/download PDF

108. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma

Author

Mignard, C., primary, Deschamps-Huvier, A., additional, Duval-Modeste, A.-B., additional, Dutriaux, C., additional, Khammari, A., additional, Avril, M.-F., additional, Mortier, L., additional, Lesimple, T., additional, Gaudy-Marqueste, C., additional, Lesage, C., additional, Machet, L., additional, Aubin, F., additional, Meyer, N., additional, Beneton Benhard, N., additional, Jeudy, G., additional, Montaudié, H., additional, Arnault, J.-P., additional, Leccia, M.-T., additional, Joly, P., additional, and Oncology Research Group Of The French Society Of Dermatology, S.F.D., additional

Published
2018
Full Text
View/download PDF

112. T‐cell papulosis associated with B‐cell malignancy: a distinctive clinicopathologic entity

Author

Visseaux, L., primary, Durlach, A., additional, Barete, S., additional, Beylot‐Barry, M., additional, Bonnet, N., additional, Chassine, A., additional, Franck, N., additional, Herve, G., additional, Leclec'h, C., additional, Machet, L., additional, Ingen‐Housz‐Oro, S., additional, Petrella, T., additional, Vergier, B., additional, Ortonne, N., additional, and Grange, F., additional

Published
2018
Full Text
View/download PDF

116. Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases

Author

Adamski, H., primary, Ingen‐Housz‐Oro, S., additional, Machet, L., additional, Carriou, A.C., additional, Ram‐Wolff, C., additional, Ortonne, N., additional, Le Gall, F., additional, Durlach, A., additional, Dupuis, J., additional, Dauriac, C., additional, Dupuy, A., additional, Grange, F., additional, and Bagot, M., additional

Published
2017
Full Text
View/download PDF

120. Incidence et impact du traitement par anti-TNFα des colites sévères sous immunothérapie du mélanome : étude MECOLIT

Author

Lesage, C., primary, Longvert, C., additional, Prey, S., additional, Maanaoui, S., additional, Dréno, B., additional, Machet, L., additional, Zehou, O., additional, Kramkimel, N., additional, Jeudy, G., additional, Skowron, F., additional, Aubin, F., additional, Visseaux, L., additional, Mansard, S., additional, and Guillot, B., additional

Published
2017
Full Text
View/download PDF

122. Corticothérapie locale brève + méthotrexate vs corticothérapie locale seule prolongée dans la pemphigoïde bulleuse : essai national multicentrique

Author

Dereure, O., primary, Bernard, P., additional, Oro, S., additional, Chosidow, O., additional, Machet, L., additional, Duvert-Lehembre, S., additional, Maillard, H., additional, Abasq, C., additional, Sassolas, B., additional, Acquitter, M., additional, Konstantinou, M.P., additional, Chaby, G., additional, Caux, F., additional, Le Roux-Villet, C., additional, Prost, C., additional, Avenel-Audran, M., additional, Delaporte, E., additional, Jeury, G., additional, Mahé, A., additional, Montaudier, H., additional, Picard-Dahan, C., additional, Quéreux, G., additional, Richard, M.-A., additional, Bourgault, I., additional, Jullien, D., additional, Tancrede-bohin, E., additional, Fichel, F., additional, Pauwels, C., additional, Sanchez, M., additional, d’Incan, M., additional, Labeille, B., additional, Mahé, E., additional, Pham-Ledard, A., additional, and Joly, P., additional

Published
2017
Full Text
View/download PDF

124. Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score ( <scp>ABSIS</scp> ) and Pemphigus Disease Area Index ( <scp>PDAI</scp> ) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus

Author

Boulard, C., Duvert Lehembre, S., Picard‐Dahan, C., Kern, J.S., Zambruno, G., Feliciani, C., Marinovic, B., Vabres, P., Borradori, L., Prost‐Squarcioni, C., Labeille, B., Richard, M.A., Ingen‐Housz‐Oro, S., Houivet, E., Werth, V.P., Murrell, D.F., Hertl, M., Benichou, J., Joly, P., Hofmann, S., Camaioni, B., Didona, B., Fania, L., Della Torre, R., Caux, F., Alexandre, M., Paul, C., Bulai Livideanu, C., Delaporte, E., Dupuy, A., Avenel‐Audran, M., Schmidt, E., Schumacher, N., Bagot, M., Tancrede‐Bohin, E., Bouaziz, J.D., D'Incan, M., Quereux, G., Skowron, F., Beylot‐Barry, M., Doutre, M.S., Bedane, C., Bernard, P., Machet, L., Jullien, ., Debarbieux, S., Dereure, O., Hünefeld, C., Schanz, S., Franck, N., Maillard, H., Misery, L., Sassolas, B., Abasq, C., Bouyeure, A.C., Lagoutte, P., Ferranti, V., and the International Pemphigus Study Group

Subjects
pemphigus vulgaris, pemphigus foliaceus, severity scores
Abstract

Background: Two pemphigus severity scores, Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI), have been proposed to provide an objective measure of disease activity. However, the use of these scores in clinical practice is limited by the absence of cut-off values that allow differentiation between moderate, significant and extensive types of pemphigus. Objectives: To calculate cut-off values defining moderate, significant and extensive pemphigus based on the ABSIS and PDAI scores. Methods: In 31 dermatology departments in six countries, consecutive patients with newly diagnosed pemphigus were assessed for pemphigus severity, using ABSIS, PDAI, Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) scores. Cut-off values defining moderate, significant and extensive subgroups were calculated based on the 25th and 75th percentiles of the ABSIS and PDAI scores. The median ABSIS, PDAI, PGA and DLQI scores of the three severity subgroups were compared in order to validate these subgroups. Results: Ninety-six patients with pemphigus vulgaris (n = 77) or pemphigus foliaceus (n = 19) were included. The median PDAI activity and ABSIS total scores were 27·5 (range 3-84) and 34·8 points (range 0·5-90·5), respectively. The respective cut-off values corresponding to the first and third quartiles of the scores were 15 and 45 for the PDAI, and 17 and 53 for ABSIS. The moderate, significant and extensive subgroups were thus defined, and had distinguishing median ABSIS (P < 0·001), PDAI (P < 0·001), PGA (P < 0·001) and DLQI (P = 0·03) scores. Conclusions: This study suggests cut-off values of 15 and 45 for PDAI and 17 and 53 for ABSIS, to distinguish moderate, significant and extensive pemphigus forms. Identifying these pemphigus activity subgroups should help physicians to classify and manage patients with pemphigus.

Published
2016

128. Les cancers cutanés rares en France : état des lieux du réseau CARADERM

Author

Blom, A., primary, Jouary, T., additional, Lebbé, C., additional, Grob, J.-J., additional, Guillot, B., additional, Combemale, P., additional, Zehou, O., additional, Bens, G., additional, Granel-Brocard, F., additional, de Quatrebarbes, J., additional, Leccia, M.-T., additional, Arnault, J.-P., additional, Dalac, S., additional, Meyer, N., additional, Machet, L., additional, Le Corre, Y., additional, Guillet, G., additional, Descamps, V., additional, Grange, F., additional, Dupuy, A., additional, Aractingi, S., additional, Saiag, P., additional, Dalle, S., additional, Cribier, B., additional, and Mortier, L., additional

Published
2016
Full Text
View/download PDF

130. Étude pilote de l’effet de la metformine dans le mélanome avancé

Author

Montaudié, H., primary, Cerezo, M., additional, Bahadoran, P., additional, Passeron, T., additional, Lehraiki, A., additional, Machet, L., additional, Arnault, J.-P., additional, Verneuil, L., additional, Maubec, E., additional, Aubin, F., additional, Granel, F., additional, Leccia, M.-T., additional, Lebbé, C., additional, Saiag, P., additional, Beylot-Barry, M., additional, Mansard, S., additional, Mortier, L., additional, Wierzbicka-Hainaut, E., additional, Giacchero, D., additional, Hofman, V., additional, Lacour, J.-P., additional, Balotti, R., additional, and Rocchi, S., additional

Published
2016
Full Text
View/download PDF

135. Papulose T associée aux hémopathies B

Author

Visseaux, L., primary, Durlach, A., additional, Barete, S., additional, Bayaram, M., additional, Beylot-Barry, M., additional, Bonnet, N., additional, Chassine, A.F., additional, Combemale, P., additional, Dhaille, F., additional, Franck, N., additional, Hervé, G., additional, Leclec’h, C., additional, Machet, L., additional, Oro, S., additional, Petrella, T., additional, Vergier, B., additional, Ortonne, N., additional, and Grange, F., additional

Published
2016
Full Text
View/download PDF

137. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan

Author

Elie N, Calvet L, Paule Opolon, Machet L, Birgit Geoerger, Jean-Marc Joseph, Jackie Morizet, Gilles Vassal, and Regairaz M

Subjects
Male, Cancer Research, Candidate gene, Angiogenesis, Biology, Irinotecan, Pleiotrophin, medicine.disease_cause, Mice, Neuroblastoma, In vivo, Gene expression, Tumor Cells, Cultured, Genetics, medicine, Animals, Humans, RNA, Messenger, RNA, Small Interfering, Molecular Biology, Oligonucleotide Array Sequence Analysis, Neovascularization, Pathologic, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Transfection, medicine.disease, Xenograft Model Antitumor Assays, Gene Expression Regulation, Drug Resistance, Neoplasm, Child, Preschool, Immunology, Cancer research, Cytokines, Camptothecin, Topoisomerase I Inhibitors, Carrier Proteins, Carcinogenesis
Abstract

In vivo neuroblastoma (NB) xenograft model, resistant to the DNA-topoisomerase I inhibitor irinotecan (CPT-11), has been established to study resistance mechanisms acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this resistance. Thus, we compared the gene expression profiles of sensitive, resistant, and reverted tumors using cDNA expression arrays. Expression of selected transcripts was confirmed by quantitative real-time PCR. We found that pleiotrophin (PTN), a heparin-binding growth factor, was the only gene significantly affected: PTN gene expression was downregulated in all resistant tumors (8-14-fold) as compared to sensitive tumors, and was increased (2-4-fold) in all reverted tumors as compared to resistant tumors. PTN thus appeared to be a likely candidate gene associated with resistance to CPT-11 in this in vivo model. To investigate the direct implication of PTN in NB, we transfected two NB cell lines with RNA interferences in order to silence PTN. PTN failed to demonstrate implication in resistance to CPT-11 in vitro but could influence sensitivity to CPT-11 exclusively through an in vivo mechanism. Indeed, vasculature was significantly enhanced in resistant NB xenografts compared to sensitive and reverted xenografts, and we suggest that PTN is acting in our resistant in vivo NB model as an angiostatic factor.

Published
2006
Full Text
View/download PDF

141. 1332P - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

Author

Dutriaux, C., Robert, C., Grob, J.J., Mortier, L., Dereure, O., Lebbe, C., Mansard, S., Grange, F., Neidhardt, E.-M., Lesimple, T., Machet, L., Bedane, C., Maillard, H., Dalac-Rat, S., Nardin, C., Szenik, A., Denden, A., and Saiag, P.

Published
2019
Full Text
View/download PDF

142. [Cutaneous mucormycosis caused by Rhizopus microsporus]

Author

Desoubeaux, G., Leperlier, M., Chaussade, H., Schneider, C., Roriz, M., Houssin, C., Rogez, C., De Muret, A., García-Hermoso, D., Bailly, E., Le Fourn, E., Machet, L., Chandenier, J., Bernard, L., Institut de génétique et microbiologie [Orsay] (IGM), and Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Aged, 80 and over, Male, Dose-Response Relationship, Drug, Biopsy, Palliative Care, Opportunistic Infections, Thrombocytopenia, Necrosis, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Adrenal Cortex Hormones, Amphotericin B, Dermatomycoses, Humans, Mucormycosis, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Rhizopus, Skin
Abstract

International audience; BACKGROUND: Mucormycosis are rare fungal infections occurring chiefly in the lung or the rhinocerebral compartment, particularly in patients with immunodeficiency or mellitus diabetes. We report the case of an elderly patient with cutaneous mucormycosis caused by Rhizopus microsporus. PATIENTS AND METHODS: An 89-year-old man presented a skin lesion of the forearm rapidly becoming inflammatory and necrotic. The patient had been treated for 2months with oral corticosteroids for idiopathic thrombocytopenia. Histological and mycological examination of the skin biopsy revealed the presence of a filamentous fungus, R. microsporus. The outcome was unfavorable, despite prescription of high-dose liposomal amphotericin B. DISCUSSION: Mucormycosis are infrequent opportunistic infections caused by angio-invasive fungi belonging to the Mucorales order. Cutaneous presentations are rare, and in rare cases the species R. microsporus is isolated in clinical samples. Diagnosis is based on histological examination highlighting the characteristic mycelium within infected tissue, together with ex vivo mycological identification using morphological and molecular methods. Treatment consists of liposomal amphotericin B combined with debridement surgery. CONCLUSION: R. microsporus is a marginal fungal species rarely isolated in clinical practice, and even less in dermatology departments. This clinical case report highlights the severity of infection with this fungus, particularly in the absence of early surgery.

Published
2014
Full Text
View/download PDF

147. A previously unreported frameshift ATP2C1 mutation in a generalized Hailey–Hailey disease.

Author

Leducq, S., Duchatelet, S., Zaragoza, J., Ventéjou, S., de Muret, A., Eymieux, S., Blanchard, E., Machet, L., Hovnanian, A., and Kervarrec, T.

Subjects
FRAMESHIFT mutation, DISEASES
Abstract

Hailey-Hailey disease (HHD; MIM 16960), also known as familial benign pemphigus, is a rare autosomal dominant acantholytic genodermatosis, with a prevalence estimated at 1/40 000.[1] HHD is characterized by recurrent grouped vesicles, blisters and erosions restricted almost entirely to the neck and symmetrical intertriginous areas.[2] HHD is caused by mutations in I ATP2C1 i ,[[3]] which encodes an intracellular calcium ATPase pump. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca(2+) pump. [Extracted from the article]

Published
2020
Full Text
View/download PDF

148. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI

Author

Hebert, V., primary, Boulard, C., additional, Houivet, E., additional, Duvert Lehembre, S., additional, Borradori, L., additional, Della Torre, R., additional, Feliciani, C., additional, Fania, L., additional, Zambruno, G., additional, Camaioni, D., additional, Didona, B., additional, Marinovic, B., additional, Schmidt, E., additional, Schumacher, N., additional, Hünefeld, C., additional, Schanz, S., additional, Johannes Steffen Kern, J.S., additional, Hofmann, S., additional, Bouyeure, A.C., additional, Picard-Dahan, C., additional, Prost-Squarcioni, C., additional, Caux, F., additional, Alexandre, M., additional, Ingen-Housz-Oro, S., additional, Bagot, M., additional, Tancrede-Bohin, E., additional, Bouaziz, J.D., additional, Franck, N., additional, Vabres, P., additional, Labeille, B., additional, Aleth Richard, M., additional, Delaporte, E., additional, Dupuy, A., additional, D’Incan, M., additional, Quereux, G., additional, Skowron, F., additional, Paul, C., additional, Bulai Livideanu, C., additional, Beylot-Barry, M., additional, Doutre, M.S., additional, Avenel-Audran, M., additional, Bedane, C., additional, Bernard, P., additional, Machet, L., additional, Maillard, H., additional, Jullien, D., additional, Debarbieux, S., additional, Sassolas, B., additional, Misery, L., additional, Abasq, C., additional, Dereure, O., additional, Lagoutte, P., additional, Ferranti, V., additional, Werth, V.P., additional, Murrell, D.F., additional, Hertl, M., additional, Benichou, J., additional, and Joly, P., additional

Published
2015
Full Text
View/download PDF

150. Corrélation entre les scores de sévérité clinique (ABSIS, PDAI, PGA), la qualité de vie (DLQI) et les taux d’Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus

Author

Houivet, E., primary, Hebert, V., additional, Boulard, C., additional, Vaillant, M., additional, Duvert Lehembre, S., additional, Borradori, L., additional, Della Torre, R., additional, Feliciani, C., additional, Fania, L., additional, Zambruno, G., additional, Camaioni, D., additional, Didona, B., additional, Marinovic, B., additional, Schmidt, E., additional, Schumacher, N., additional, Hünefeld, C., additional, Schanz, S., additional, Johannes Steffen Kern, J.S., additional, Hofmann, S., additional, Bouyeure, A.C., additional, Picard-Dahan, C., additional, Prost-Squarcioni, C., additional, Caux, F., additional, Alexandre, M., additional, Ingen-Housz-Oro, S., additional, Bagot, M., additional, Tancrede-Bohin, E., additional, Bouaziz, J.D., additional, Franck, N., additional, Vabres, P., additional, Labeille, B., additional, Aleth Richard, M., additional, Delaporte, E., additional, Dupuy, A., additional, D’Incan, M., additional, Quereux, G., additional, Skowron, F., additional, Paul, C., additional, Bulai Livideanu, C., additional, Beylot-Barry, M., additional, Doutre, M.S., additional, Avenel-Audran, M., additional, Bedane, C., additional, Bernard, P., additional, Machet, L., additional, Maillard, H., additional, Jullien, D., additional, Debarbieux, S., additional, Sassolas, B., additional, Misery, L., additional, Abasq, C., additional, Dereure, O., additional, Lagoutte, P., additional, Ferranti, V., additional, Werth, V.P., additional, Murrell, D.F., additional, Hertl, M., additional, Benichou, J., additional, and Joly, P., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results